COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively worldwide. For current information on the number of cases and fatalities, see the Centers for Disease Control and Prevention: COVID Data Tracker and the World Health Organization's Novel Coronavirus (COVID-2019) situation reports.
Transmission of COVID-19
The SARS-CoV-2 virus spreads by close person-to-person contact, mainly via respiratory droplets produced when an infected person coughs, sneezes, sings, exercises, or talks. The spread occurs through large respiratory droplets that can travel short distances and land directly on mucosal surfaces or through small respiratory particle aerosols that can linger in air for several hours and travel longer distances (>6 feet) before being inhaled. Spread of the virus could also occur via contact with a surface contaminated by respiratory droplets. It is known that asymptomatic and presymptomatic people, as well as symptomatic patients, can transmit the virus, making it difficult to control an outbreak.
A person is most contagious for the several days before and after the onset of symptoms, at which time the viral load in respiratory secretions is greatest. The SARS-CoV-2 virus spreads easily between people. The risk of transmission is directly related to the amount of virus to which a person is exposed. In general, the closer and longer the interaction with an infected person, the higher the risk of virus spread. Factors such as distance from an infected person, duration of time in the presence of an infected person, the size of the air space, and the direction and speed of airflow can contribute to this risk. The Delta variant of the SARS-CoV-2 virus is more readily transmitted than the earlier variants (see CDC: Delta Variant: What We Know About the Science).
Super-spreader events or situations played an extraordinary role in driving the 2003 SARS outbreak and also play a major role in the current COVID-19 outbreak. Super-spreading situations are those in which a small number of cases contribute a large proportion of the disease's transmission. This is probably due to a combination of biological, environmental, and behavioral factors.
Situations with high risk of transmission include congregate living facilities (eg, nursing homes, long-term care facilities, prisons, ships) as well as crowded, poorly ventilated environments such as indoor religious services, gyms, bars, night clubs, indoor restaurants, and meat-packing facilities. Such situations involve high population density and often difficulty in maintaining avoidance precautions. The residents of nursing homes are also at high risk of severe disease because of age and underlying medical disorders.
Quarantine and isolation
Quarantine and isolation measures are being applied in an attempt to limit the local, regional, and global spread of this outbreak. See also Centers for Disease Control and Prevention (CDC) discussion of Contact Tracing for COVID-19 which includes quarantine and isolation recommendations.
A close contact is a person who
Was within 6 feet of an infected person for a total of 15 minutes or more over a 24-hour period starting from 48 hours before the onset of symptoms or positive test (if asymptomatic)
Other situations that could be taken into account in considering whether a person is a close contact include whether the person had direct physical contact with the sick person (eg, hugged or kissed them, shared eating or drinking utensils) or if the infected person was likely to be generating significant respiratory aerosols (eg, was sneezing, coughing, singing, shouting). The CDC recommends not taking into account whether the contact person was wearing a mask.
Quarantine is meant to separate and restrict the movement of close contacts who were exposed to a contagious person to see if they become sick. The recommended duration is based on the incubation period of the pathogen, which is up to 14 days for the SARS-CoV-2 virus. (Also see CDC: When to Quarantine.) The following people should quarantine for 14 days after their last exposure:
Asymptomatic close contacts testing negative
Asymptomatic close contacts who have not been tested (excluding people who have had COVID-19 within the past 3 months)
People who have been fully vaccinated against the disease and show no symptoms do not need to quarantine after a close contact with someone who had COVID-19. However, fully vaccinated people should get tested 3 to 5 days after their exposure (even if they do not have symptoms) and wear a mask indoors in public for 14 days following exposure or until their test result is negative.
Isolation is meant to separate people who are contagious from those who are susceptible. The recommended duration is based on the patient's symptoms as well as data on the time course of recovery of cultivatable SARS-CoV-2 virus from upper respiratory secretion. (Also see CDC: Duration of Isolation and Precautions for Adults with COVID-19.) The following people should isolate:
People with COVID-19 symptoms who have not been tested
Anyone testing positive for SARS-CoV-2 (whether symptomatic or asymptomatic)
Isolation and precautions for patients who had mild to moderate symptoms can be discontinued for most patients 10 days after symptom onset provided they have been afebrile for ≥ 24 hours without the use of fever-reducing drugs and whose other symptoms are significantly improving. Asymptomatic patients can discontinue isolation 10 days after the date of their first positive SARS-CoV-2 diagnostic test.
Strict adherence to these measures have been successful at controlling the spread of infection in select areas.
Symptoms and Signs of COVID-19
People with COVID-19 may have few to no symptoms, although some become severely ill and die. Symptoms can include
Shortness of breath or difficulty breathing
Chills or repeated shaking with chills
New loss of smell or taste
Congestion or runny nose
Nausea or vomiting
The incubation time (ie, from exposure to symptom onset) ranges from 2 to 14 days, with a median of 4 to 5 days. The majority of infected people (likely 80%) will have no symptoms or mild disease. The risk of serious disease and death in COVID-19 cases increases with age, in people who smoke, and in people with other serious medical disorders, such as cancer, heart, lung, kidney, or liver disease, diabetes, immunocompromising conditions, sickle cell disease, or obesity (see CDC: Symptoms of COVID-19 and Different Groups of People at Increased Risk for Severe Illness). Risk of serious disease and death decreases in people who are vaccinated against COVID-19. Severe disease is characterized by dyspnea, hypoxia, and extensive lung involvement on imaging. This can progress to respiratory failure requiring mechanical ventilation, shock, multiorgan failure, and death.
In addition to respiratory disease that can progress to acute respiratory distress syndrome (ARDS Acute Hypoxemic Respiratory Failure (AHRF, ARDS) Acute hypoxemic respiratory failure is severe arterial hypoxemia that is refractory to supplemental oxygen. It is caused by intrapulmonary shunting of blood resulting from airspace filling or... read more ) and death, other serious complications include the following:
Heart disorders including arrhythmias Overview of Arrhythmias The normal heart beats in a regular, coordinated way because electrical impulses generated and spread by myocytes with unique electrical properties trigger a sequence of organized myocardial... read more , cardiomyopathy Overview of Cardiomyopathies A cardiomyopathy is a primary disorder of the heart muscle. It is distinct from structural cardiac disorders such as coronary artery disease, valvular disorders, and congenital heart disorders... read more , and acute cardiac injury
Coagulation disorders including thromboembolism and pulmonary emboli Pulmonary Embolism (PE) Pulmonary embolism (PE) is the occlusion of pulmonary arteries by thrombi that originate elsewhere, typically in the large veins of the legs or pelvis. Risk factors for pulmonary embolism are... read more , disseminated intravascular coagulation (DIC) Disseminated Intravascular Coagulation (DIC) Disseminated intravascular coagulation (DIC) involves abnormal, excessive generation of thrombin and fibrin in the circulating blood. During the process, increased platelet aggregation and coagulation... read more , hemorrhage, and arterial clot formation
Sepsis Sepsis and Septic Shock Sepsis is a clinical syndrome of life-threatening organ dysfunction caused by a dysregulated response to infection. In septic shock, there is critical reduction in tissue perfusion; acute failure... read more , shock Shock Shock is a state of organ hypoperfusion with resultant cellular dysfunction and death. Mechanisms may involve decreased circulating volume, decreased cardiac output, and vasodilation, sometimes... read more , and multiorgan failure
A rare postinfectious inflammatory syndrome termed multisystem inflammatory syndrome in children (MIS-C) has been observed as a rare complication of SARS-CoV-2 infection. It has features similar to Kawasaki disease Kawasaki Disease Kawasaki disease is a vasculitis, sometimes involving the coronary arteries, that tends to occur in infants and children between the ages of 1 year and 8 years. It is characterized by prolonged... read more or toxic shock syndrome Toxic Shock Syndrome (TSS) Toxic shock syndrome is caused by staphylococcal or streptococcal exotoxins. Manifestations include high fever, hypotension, diffuse erythematous rash, and multiple organ dysfunction, which... read more . Children with MIS-C most commonly present with fever, tachycardia, and gastrointestinal symptoms with signs of systemic inflammation. Cases meeting the following criteria should be reported to the Centers for Disease Control and Prevention (CDC) as suspected MIS-C: individuals < 21 years old with fever > 24 hours, laboratory evidence of inflammation, signs of ≥ 2 organs involved, and laboratory or epidemiologic association with SARS-CoV-2 infection (1 Symptoms and signs references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). A similar multisystem inflammatory syndrome in young and middle-aged adults (MIS-A) also has been reported (2 Symptoms and signs references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ).
Dermatologic manifestations may be associated with COVID-19 (see CDC: Interim Clinical Guidance/Dermatologic Manifestations).
In most patients, symptoms resolve over about a week. However, some patients clinically deteriorate after a week, progressing to severe disease including ARDS Acute Hypoxemic Respiratory Failure (AHRF, ARDS) Acute hypoxemic respiratory failure is severe arterial hypoxemia that is refractory to supplemental oxygen. It is caused by intrapulmonary shunting of blood resulting from airspace filling or... read more . Even patients with mild illness (about one third in one study) may have persistent symptoms including dyspnea, cough, and malaise, which can last for weeks or even months. More prolonged illness appears to be more common in those with severe disease. Viral PCR tests in patients may remain positive for at least 3 months regardless of symptoms. However, even patients with lingering symptoms are generally not considered infectious, as virus is rarely if ever able to be cultured from the upper respiratory tract of patients after 10 days of illness.
Although infection with coronaviruses is generally believed to confer some degree of immunity to reinfection, the duration and effectiveness of immunity following COVID-19 remain unknown. Researchers have demonstrated the presence of neutralizing antibodies in most patients following SARS-CoV-2 infection. These antibody titers appear to wane over time; the clinical significance of this is unclear. However, recently, a very small number of cases have been reported in which a genetically different strain of SARS-CoV-2 was identified in recovered patients who manifested recurrent symptoms of COVID-19 (or a few who were asymptomatic). The fact that a genetically different strain was detected strongly suggests that these few cases represent reinfection rather than reactivation of disease. This is more likely to occur >3 months after the initial infection but may be considered if symptoms recur as soon as 45 days after the initial infection (see CDC: Investigative Criteria for Suspected SARS-CoV-2 Reinfection).
Symptoms and signs references
1. Feldstein LR, Rose EB, Horwitz SM, et al: Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 383(4):334-346, 2020. doi:10.1056/NEJMoa2021680
2. Morris SB, Schwartz NG, Patel P, et al: Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep 69:1450–1456, 2020. doi: 10.15585/mmwr.mm6940e1
Diagnosis of COVID-19
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and other nucleic acid amplification testing (NAAT) of upper and lower respiratory secretions
Antigen testing of upper and lower respiratory secretions
People with signs or symptoms of COVID-19 Symptoms and Signs of COVID-19 COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more should be tested. Also, people who were exposed to a person with COVID-19 may be tested as part of contact tracing. Point-of-care testing can provide rapid results and be critical to identifying asymptomatic cases needed to interrupt SARS-CoV-2 transmission such as part of routine screening at workplaces or other settings, especially when community transmission levels are high. See (CDC: Overview of Testing for SARS-CoV-2)
Diagnostic testing for COVID-19 is becoming increasingly available through commercial and hospital-based laboratories in addition to public health laboratories. The diagnostic test type choice and its interpretation should be influenced by the likelihood of the person having COVID-19 based on the prevalence of SARS-CoV-2 in the population and the presence of COVID-19 symptoms, signs, or close contacts. RT-PCR has the highest sensitivity and specificity and is the preferred initial test for COVID-19, particularly in people with signs or symptoms of COVID-19 or close exposure to someone with COVID-19. Point-of-care antigen detection and NAATs are also commercially available. These assays typically are less sensitive than standard RT-PCR assays. It may be necessary to confirm some antigen test results (eg, a negative test in a person with symptoms or a positive test in a person without symptoms) with a laboratory-based RT-PCR.
For initial diagnostic testing for COVID-19, the CDC recommends collecting and testing a single upper respiratory specimen. The following are acceptable specimens:
A nasopharyngeal specimen collected by a healthcare professional (preferred specimen if available)
An oropharyngeal (throat) specimen collected by a healthcare professional
A nasal mid-turbinate swab collected by a healthcare professional or by a supervised onsite self-collection (using a flocked tapered swab)
An anterior nares specimen collected by a healthcare professional or by onsite or home self-collection (using a flocked or spun polyester swab)
A nasopharyngeal wash/aspirate or nasal wash/aspirate specimen collected by a healthcare professional
A saliva specimen collected by supervised self-collection
Refer to accepting laboratory's collection instructions, because not all testing platforms and laboratories may be able to test all specimen types. For nasopharyngeal and oropharyngeal specimens, use only synthetic fiber swabs with plastic or wire shafts. Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing. The swabs should be placed immediately into a sterile transport tube containing 2 to 3 mL of either viral transport medium, Amies transport medium, or sterile saline, unless using a test designed to analyze the specimen directly, such as a point-of-care test. Maintain proper infection control when collecting specimens.
The CDC also recommends testing lower respiratory tract specimens, if available. For patients for whom it is clinically indicated (eg, those receiving invasive mechanical ventilation), a lower respiratory tract aspirate or bronchoalveolar lavage sample should be collected and tested as a lower respiratory tract specimen. Collection of sputum should be done only for those patients with productive coughs. Induction of sputum is not recommended. (See CDC: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease.) For biosafety reasons, the CDC recommends local institutions do not attempt to isolate the virus in cell culture or do initial characterization of viral agents in patients suspected of having COVID-19 infection.
Positive test results need to be reported to local and state health departments, and patients require strict isolation at home or in a healthcare facility.
NOTE: Serologic, or antibody, testing should not be used to diagnose acute COVID-19 illness, because antibodies most commonly become detectable only 1 to 3 weeks after symptom onset. Antibody tests help determine whether the person being tested was previously infected and are important for surveillance and epidemiologic studies.
Routine laboratory findings for those with more severe disease include lymphopenia as well as less specific findings of elevated aminotransaminase (ALT, AST) levels, elevated lactate dehydrogenase (LDH) levels, D-dimer, ferritin, and elevated inflammatory markers such as C-reactive protein.
Chest imaging findings can be normal with mild disease and increase with increasing severity of the illness. Typical findings are consistent with viral pneumonia and include ground-glass opacities and consolidation on either chest x-ray or chest CT. Chest imaging is not recommended as a routine screening tool for COVID-19.
Treatment of COVID-19
Sometimes, remdesivir for severe disease
Sometimes, dexamethasone for severe disease
Sometimes, monoclonal antibodies
Treatment of COVID-19 depends on the severity of illness. The CDC definitions of severity are as follows:
Mild illness: Patients who have any signs and symptoms of COVID-19 (eg, fever, cough, sore throat, malaise, headache, muscle pain) but without shortness of breath, dyspnea, or abnormal chest imaging
Moderate illness: Patients who have evidence of lower respiratory disease by clinical assessment or imaging, and an oxygen saturation (SpO2) ≥ 94% on room air at sea level
Severe illness: Patients who have respiratory rate > 30 breaths per minute, SpO2 < 94% on room air at sea level (or, for patients with chronic hypoxemia, a > 3% decrease from baseline), ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mmHg, or lung infiltrates > 50%
Critical illness: Patients who have respiratory failure, septic shock, and/or multiple organ dysfunction
Treatment of COVID-19 is mainly supportive. Many treatment clinical trials are currently registered, but data on effective therapy remain sparse. The antiviral agent remdesivir is the only treatment approved by the US Food and Drug Administration (FDA) for COVID-19. It is approved for use in patients ≥12 years of age and ≥ 40 kg who require hospitalization for COVID-19. It also remains available through an FDA emergency use authorization for hospitalized pediatric patients ≥ 3.5 kg and not otherwise covered under the approval, regardless of age. Current national guidelines caution against the use of therapeutic agents outside of clinical trials with the exception of remdesivir and dexamethasone (see National Institutes of Health (NIH) COVID-19 Treatment Guidelines and Infectious Diseases Society of America (IDSA) Guidelines on the Treatment and Management of Patients with COVID-19). For each therapeutic agent, the benefits must be weighed against possible risks for each patient.
The NIH treatment guidelines on corticosteroids recommend using dexamethasone (at a dose of 6 mg once per day for up to 10 days or until hospital discharge, whichever comes first) in patients with COVID-19 who are mechanically ventilated or require supplemental oxygen but recommend against using dexamethasone in patients who do not require supplemental oxygen. If dexamethasone is not available, other glucocorticoids (eg, prednisone, methylprednisolone, hydrocortisone) may be used.
The NIH treatment guidelines on remdesivir recommend using this drug for 5 days or until hospital discharge, whichever comes first, in hospitalized patients with COVID-19 who require supplemental oxygen but who do not require invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Remdesivir is not recommended for patients with an eGFR <30 mL/minute. Renal function should be monitored before and during remdesivir treatment.
The NIH treatment guidelines on immunomodulators recommend using additional immunomodulatory therapy in the following situations: baricitinib (a JAK inhibitor) or tocilizumab (an IL-6 inhibitor) in select recently hospitalized patients requiring oxygen delivery through a high-flow device or noninvasive ventilation with rapidly increasing oxygen needs and systemic inflammation. Addition of tocilizumab is recommended in select patients recently admitted to the intensive care unit (ICU) requiring invasive mechanical ventilation or ECMO. See guidelines for further details regarding appropriate patient selection for these therapies.
The FDA has issued an emergency use authorization (EUA) for 3 monoclonal antibody therapies (bamlanivimab plus etesevimab, casirivimab plus imdevimab, sotrovimab) for the treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years and weighing ≥ 40 kilograms) with COVID-19 and who are at high risk for progressing to severe disease (includes those who are ≥65 years or who have certain chronic medical conditions). An NIH panel recommended using one of the following anti-SARS-CoV-2 monoclonal antibodies to treat nonhospitalized patients with mild to moderate COVID-19 who are at high risk of clinical progression (see NIH COVID-19 Treatment Guidelines: Anti-SARS-CoV-2 Monoclonal Antibodies [October 19, 2021]):
Casirivimab plus imdevimab (more commonly referred to as Regeneron antibody therapy)
The panel currently recommends against the use of bamlanivimab plus etesevimab in these patients due to an increase in the prevalence of potentially resistant variants.
A placebo-controlled trial of high-titer convalescent plasma in older patients with mild symptoms for less than 72 hours showed a significant reduction in the development of severe respiratory disease (1 Treatment references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). The NIH treatment guidelines recommend against the use of nonspecific immunoglobulin (IVIG), and the treatment guidelines recommend against the use of mesenchymal stem cell therapy. Additional immunomodulatory therapies, including interferons, kinase inhibitors, and interleukin inhibitors have been used, but there are insufficient data to recommend their routine use outside of clinical trials. Other drugs that have been used include azithromycin and antiretrovirals. There are also insufficient data to support the use of these agents outside of clinical trials. Multiple clinical trials of the HIV retroviral lopinavir/ritonavir and the anti-malaria drugs chloroquine and hydroxychloroquine have shown these drugs to be without benefit. There are also no randomized clinical trials documenting the usefulness of the anti-parasite drug ivermectin for the prevention or treatment of COVID-19 (2 Treatment references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). The FDA and other organizations have issued warnings about toxicity from the inappropriate use of ivermectin preparations intended for large animal use (see FDA: Why You Should Not Use Ivermectin to Treat or Prevent COVID-19).
Toxicities associated with chloroquine and hydroxychloroquine led to an NIH recommendation that they not be used for treatment of COVID-19 in hospitalized patients. In nonhospitalized patients, the NIH guidelines recommend against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19 outside of a clinical trial.
Supportive therapy may include critical care management with mechanical ventilation and vasopressor support. Early goals of care discussions are recommended. For patients with severe respiratory failure, extracorporeal membrane oxygenation (ECMO) may be considered. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score developed based on a study of 2355 adult patients with severe acute respiratory failure treated by ECMO from 2000 to 2012 (3 Treatment references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ) predicts survival in adults receiving ECMO for respiratory failure and may help in the selection of COVID-19 patients for ECMO treatment but is not a substitute for clinical assessment and judgment. A study on the use of ECMO in 1035 patients with acute hypoxic respiratory failure due to COVID-19 found that the death rate was less than 40%, which is comparable to results in non-COVID-19 patients with acute hypoxic respiratory failure (4 Treatment references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). However, as of December 2020, the NIH panel concluded there is insufficient evidence to recommend either for or against the use of ECMO in adults with COVID-19 and refractory hypoxemia (see NIH COVID-19 Treatment Guidelines: Extracorporeal Membrane Oxygenation [December 17, 2020]).
Complications of COVID-19 illness should also be treated as they arise. Hospitalized patients with COVID-19 may be at increased risk for thromboembolic events. Pharmacologic prophylaxis should be given as per hospital guidelines, and a high clinical suspicion for thromboembolic events should be maintained. Therapeutic anticoagulation should be started if there is a high suspicion of thromboembolism and confirmatory imaging could not be obtained.
Drugs such as angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy should be continued if needed for concomitant medical conditions but not started as treatment for COVID-19. There is no evidence that use of nonsteroidal anti-inflammatory drugs (NSAIDs) is linked to worse outcomes, and either acetaminophen or NSAIDs can be used during the treatment of COVID-19.
Respiratory management of the nonintubated and intubated COVID-19 patient should take into consideration the tendency toward hypoxia. Nonpharmacologic adjunctive measures such as frequent repositioning and ambulation may be helpful. Therapeutic decisions should be made to best manage the patient, but also consider the risk of exposure to healthcare workers and best use of resources. Intubation is a time of particular risk of healthcare provider exposure to infectious aerosols and should be done with extreme care.
Libster R, Pérez Marc G, Wappner D, et al: Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med, 2021. doi: 10.1056/NEJMoa2033700. Epub ahead of print. PMID: 33406353.
Popp M, Stegemann M, Metzendorf MI, et al: Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 7(7):CD015017, 2021. doi: 10.1002/14651858.CD015017.pub2
Schmidt M, Bailey M, Sheldrake J, et al: Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med 189(11):1374-1382, 2014. doi:10.1164/rccm.201311-2023OC
Barbaro RP, MacLaren G, Boonstra PS, et al: Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet, 2020. [Epub ahead of print] doi: 10.1016/S0140-6736(20)32008-0
Prevention of COVID-19
To help prevent spread of SARS-CoV-2 from suspected cases, health care practitioners should use standard, contact, and airborne or droplet precautions with eye protection. Airborne precautions are particularly relevant for patients undergoing aerosol-generating procedures. Patients with respiratory symptoms should be identified and masked immediately upon entry to any healthcare facility. Strategies to monitor and conserve personal protective equipment (PPE) supplies should be considered; tools are available through the CDC. (See CDC: Infection Control Guidance for Healthcare Professionals about Coronavirus.)
The best way to prevent illness is for people to avoid exposure to the virus. The following steps are recommended by the CDC:
Maintain good social distance (about 6 feet) and avoid crowds and poorly ventilated spaces
Wear a face mask covering both mouth and nose when around others, especially when indoors
Wash hands often with soap and water; use hand sanitizer with ≥ 60% alcohol if soap and water are unavailable
Routinely clean and disinfect frequently touched surfaces
To maximize protection from the Delta variant and prevent possible transmission of this virus to others, fully vaccinated people should wear a mask indoors in public if they are in an area of substantial or high transmission. They may also be required to wear a mask by local laws, regulations, or rules or business or workplace guidance. Wearing a mask is most important for people with a weakened immune system or for people at increased risk for severe disease because of age or an underlying medical condition. Wearing a mask is also important for people who have someone in their household who has a weakened immune system, is at increased risk for severe disease, or is unvaccinated. People who are at increased risk for severe disease or who have someone in their household at increased risk might choose to wear a mask regardless of the level of transmission. (Also see CDC: When You've Been Fully Vaccinated [July 27, 2021].)
Areas of sustained transmission will vary as the outbreak proceeds. For areas inside the US, clinicians should consult state or local health departments. Cases have been reported in all states. The CDC advises that travel increases the chance of getting and spreading COVID-19 and recommends avoiding all cruise ship travel due to the global pandemic; for current information see CDC: Coronavirus Disease Information for Travel.
Multiple COVID-19 vaccines are currently in use worldwide. In the US, 3 vaccines have received either full approval or emergency use authorization (EUA) from the US Food and Drug Administration (FDA):
The Pfizer-BioNTech COVID-19 vaccine (mRNA) received full FDA approval on August 24, 2021 for use in individuals ≥ 16 years of age and is available under EUA for use in individuals 5 to15 years of age. It is given as a series of 2 intramuscular injections, 3 weeks apart. (See also FDA: Fact Sheet for Healthcare Providers [Pfizer-BioNTech].)
The Moderna COVID-19 vaccine (mRNA) received EUA on December 18, 2020 for use in individuals ≥ 18 years of age and also requires 2 injections but given 4 weeks apart. (See also FDA: Fact sheet for Healthcare Providers [Moderna].)
The Johnson & Johnson COVID-19 vaccine (adenovirus vector) received EUA on February 27, 2021 for use in individuals ≥ 18 years of age and requires a single injection. (See also FDA: Fact sheet for Healthcare Providers [Janssen].)
These 3 COVID-19 vaccines target the spike protein that is distinctive to the virus and is critical to the virus's attack on host cells using various methods. The Pfizer and Moderna vaccines do not contain viral antigen but rather deliver a small, synthetic piece of mRNA that encodes for the desired target antigen (the spike protein). After being taken up by cells of the immune system, the vaccine mRNA degrades after instructing the cell to produce viral antigen. The antigen is then released and triggers the desired immune response to prevent severe infection upon subsequent exposure to the actual virus. The Johnson & Johnson vaccine uses an adenoviral vector platform which contains a piece of the DNA, or genetic material, that is used to make the distinctive “spike” protein of the SARS-CoV-2 virus which then triggers the desired immune response.
In August 2021, the FDA amended the EUA for the Pfizer and Moderna vaccines to allow an additional dose to be administered to people with moderately to severely compromised immune systems after an initial 2-dose series. The additional dose should be administered at least 28 days following the 2-dose regimen of the same vaccine to individuals age ≥ 18 years (age ≥ 12 years for Pfizer) who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Third doses (booster doses) are available for all Pfizer and Moderna vaccine recipients who are age ≥ 18 years and who completed their initial 2-dose series at least 6 months ago. Second doses (booster doses) are recommended for Johnson & Johnson vaccine recipients who are age ≥ 18 years and who received their first dose ≥ 2 months ago. Eligible people may choose to receive a booster dose of any available COVID-19 vaccine (Pfizer, Moderna, or Johnson & Johnson), regardless of which vaccine they initially received. (See CDC: COVID-19 Booster Shots.)
The Pfizer and Moderna vaccines are contraindicated in individuals with known history of severe allergic reaction (eg, anaphylaxis) to a previous dose of the vaccines or any component of these vaccines (including polyethylene glycol [PEG]). The Johnson & Johnson vaccine is contraindicated in individuals with a history of severe allergic reaction to any of its component (including polysorbate 80).
FDA warnings about the vaccines are as follows:
Appropriate medical treatment used to manage immediate allergic reactions must be immediately available at the site of vaccination.
Immunocompromised people, including those taking immunosuppressant therapy, may have a diminished response to the vaccine.
The vaccine may not protect all vaccine recipients.
Thrombosis with thrombocytopenia has been reported following use of the Johnson & Johnson vaccine. The reports suggest an increased risk of thrombosis involving the cerebral venous sinuses and other sites (including but not limited to the large blood vessels of the abdomen and the veins of the lower extremities) combined with thrombocytopenia and with onset of symptoms approximately 1 to 2 weeks after vaccination. Most cases of thrombosis with thrombocytopenia reported following the Johnson & Johnson vaccine have occurred in females ages 18 to 49 years; some have been fatal. In individuals with suspected thrombosis with thrombocytopenia following the Johnson & Johnson vaccine, the use of heparin may be harmful and alternative treatments may be needed. Consultation with hematology specialists is strongly recommended.
Myocarditis Myocarditis Myocarditis is inflammation of the myocardium with necrosis of cardiac myocytes. Myocarditis may be caused by many disorders (eg, infection, cardiotoxins, drugs, and systemic disorders such... read more and pericarditis Pericarditis Pericarditis is inflammation of the pericardium, often with fluid accumulation. Pericarditis may be caused by many disorders (eg, infection, myocardial infarction, trauma, tumors, metabolic... read more have been reported following the second doses of the Pfizer and Moderna vaccines, suggesting there may be an increased risk of these events following vaccination. Vaccine recipients should seek medical attention right away if they have chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after vaccination.
The 3 COVID-19 vaccines have similar adverse effects. Rare severe allergic reactions, including anaphylaxis, have been reported. The following adverse effects are common:
Pain, swelling, and redness at the injection site
Adverse effects typically last several days. For vaccines requiring two doses, more people experience adverse effects after the second dose than after the first dose. Clinical trials did not reveal serious safety concerns. There is a remote chance of a severe allergic reaction that usually occurs within a few minutes to 1 hour after getting a dose of the vaccine. Individuals with a history of severe (anaphylactic) reaction to a vaccine or injectable medication should be counseled on this potential risk and vaccinated in a supervised setting capable of responding to an anaphylactic reaction.
The 3 vaccines that received FDA approval or EUA have shown similar efficacy in clinical trials with near complete prevention of serious complications from COVID-19 such as hospitalization and death. The Pfizer vaccine is 95% effective in preventing COVID-19 disease following 2 doses in healthy adults (1 Vaccination references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). The efficacy of the vaccine is based on a randomized, placebo-controlled clinical trial with over 43,000 participants in which 8 cases of COVID-19 were observed in vaccine recipients and 162 were observed with placebo. The initial studies of the Moderna vaccine in over 30,000 participants showed similar efficacy of 94.1%. The Johnson & Johnson vaccine studies with over 39,000 participants, including those in regions of the world where newer variants are circulating, showed an overall efficacy of approximately 67% in preventing moderate to severe/critical COVID-19 occurring at least 14 days after vaccination and 85% in preventing severe/critical COVID-19 occurring at least 28 days after vaccination. The various clinical trials should not be compared directly, because they were done on different patient populations at different time points during the pandemic using slightly different endpoints. The duration of protection of all of the vaccines is currently not known. Also, there are limited data on the impact vaccination will have on the transmission of SARS-CoV-2. Therefore, it is recommended that vaccinated people continue to adhere to general infection-prevention guidelines such as mask wearing, social distancing, and frequent hand washing.
The effectiveness of the Pfizer vaccine against symptomatic disease caused by the Delta variant in the United Kingdom was assessed after a single dose and after 2 doses. After 2 doses, the Pfizer vaccine was 93.7% effective among patients with the alpha variant and 88.0% among those with the Delta variant. A single dose of the vaccine was markedly less effective against either variant and was especially less effective against the Delta variant (2 Vaccination references COVID-19 is an acute, sometimes severe, respiratory illness caused by a novel coronavirus SARS-CoV-2. COVID-19 was first reported in late 2019 in Wuhan, China and has since spread extensively... read more ). All vaccines available in the US remain highly effective at preventing severe disease, specifically hospitalization and death, from all currently circulating variants. Recent US data show that unvaccinated people are 29 times more likely to be hospitalized with COVID-19 than unvaccinated people (see CDC: SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021).
1. Lurie N, Saville M, Hatchett R, et al: Developing COVID-19 vaccines at pandemic speed. N Engl J Med 382(21):1969-1973, 2020. doi: 10.1056/NEJMp2005630
2. Lopez Bernal J, Andrews N, Gower C, et al: Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 385(7):585-594, 2021. doi:10.1056/NEJMoa2108891
The following English-language resources may be useful. Please note that THE MANUAL is not responsible for the content of these resources.